The DARPin platform
Molecular Partners uses its DARPin platform to create custom therapeutic responses by combining defined biological effects in modular ways, advancing programs toward clinical trials.
molecularpartners.comCrawled Nov 18, 2026
Molecular Partners uses its DARPin platform to create custom therapeutic responses by combining defined biological effects in modular ways, advancing programs toward clinical trials.
The page provides information on participating in Molecular Partners’ clinical trials, including ongoing studies and expert contacts.
Explore DARPin Science, multi-functional protein therapeutics by Molecular Partners, redefining drug design.
Molecular Partners reports that its legacy oncology candidates, MP0250 and MP0274, show promising biological activity and are well tolerated, informing the development of other candidates.
The page describes partnerships between Molecular Partners and Orano Med, Novartis, and AbbVie to develop DARPin therapies.
The page explains Molecular Partners’ DARPin platform and its therapeutic candidates targeting oncology and other diseases.
Molecular Partners AG today announced that it has entered into a strategic research collaboration and option agreement with Janssen Biotech, Inc. to research, discover and develop DARPin products for the treatment of immunological diseases.
Molecular Partners announced today that the results of a Phase I/II study evaluating the safety and preliminary activity of MP0112, a long-acting anti-VEGF DARPin, in patients with Diabetic Macular Edema (DME)
On February 16th 2005, Molecular Partners AG has been awarded the Swiss Technology Award 2005 for their designed repeat protein (DRP) technology.
Molecular Partners offers career opportunities in biotech, focusing on next-generation therapies.
James Cook serves on the Scientific Advisory Board of Molecular Partners, which he joined in 2025. He is President of newcleo Americas and previously founded Evergreen Theragnostics, serving as its President and CEO before its acquisition by Lantheus.
Jason Lewis serves on the Scientific Advisory Board of Molecular Partners, which he joined in 2025. He holds the Emily Tow Chair at Memorial Sloan Kettering Cancer Center (MSKCC) and is Deputy Director at the Sloan Kettering Institute, overseeing its Office of Scientific Education and Training.
Ken Herrmann chairs the Scientific Advisory Board of Molecular Partners, which he joined in 2025. He is Professor of Nuclear Medicine at the University Hospital Essen and Section Editor of *The Journal of Nuclear Medicine*, and previously chaired the European Association of Nuclear Medicine (EANM) Oncology & Theranostics Committee.
Michael Morris serves on the Scientific Advisory Board of Molecular Partners, which he joined in 2025. He holds the Steven A. Greenberg Chair in Prostate Cancer Research and leads the Prostate Cancer section of the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center (MSKCC).
Contact information for general inquiries and media relations is provided, including addresses for headquarters in Zurich-Schlieren, Switzerland, and media contacts.
Molecular Partners develops DARPin-based therapeutics for cancer and serious diseases through oncology and radiopharmaceutical programs.